Emerging Companies

June 23, 2014

The Jumpstart Our Business Startup (JOBS) Act marks a key departure from the previous one-size...

January 24, 2014

Ron Cohen MD, President and Chief Executive Officer, Acorda Therapeutics, Inc., discusses what...

October 25, 2013

BIO featured Jan Lundberg of Eli Lilly as this year's fireside chat speaker at the BIO...

October 25, 2013

Stephan Tanda, Managing Board Member with Royal DSM, discusses what is necessary to create an...

April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
September 4 2014
Washington, D.C. (September 4, 2014) – The Biotechnology Industry Organization (BIO) is pleased to announce the winners of the 2014 BIO Investor Forum Buzz of BIO contest, which recognizes highly innovative companies in the biotech sector. Taking place October 7-8, 2014 at the Palace Hotel in San Francisco, California, the 13th Annual BIO Investor Forum will focus on investment opportunities for early stage and established private companies as well as emerging public companies.
August 6 2014
Survey responses will help inform Prescription Drug User Fee Act VI negotiations
May 9 2014
Bill would strengthen, make permanent critical R&D tax credit
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.